Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.
Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.